News

Declaration of Effectiveness in Face of 9 Major SARS-CoV-2 Variants

News
2021-04-27

We Bioperfectus today solemnly and sincerely declare that our products:COVID-19 Coronavirus Real Time PCR Kit &COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit STAY NO DROP IN SENSITIVITY & SPECIFICITY IN FACE OF 9 MAJOR VARIANTS OF SARS-COV-2.

 Information about 9 Major SARS-CoV-2 Variants

Lineage

First Detected

Earliest Day

Spike Protein Substitutions

Attributes

B.1.1.7

United Kingdom

February 7, 2020

Δ69/70, Δ144, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)

~50% increased transmission

Likely increased severity based on hospitalizations and case fatality rates

Minimal impact on neutralization by EUA monoclonal antibody treatments

Minimal impact on neutralization by convalescent and post-vaccination sera

B.1.351

South Africa

May 11, 2020

D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V

~50% increased transmission

Reduction in neutralization by some, but not all EUA monoclonal antibody treatments

Moderate reduction in neutralization by convalescent and post-vaccination sera

P.1

Japan/
Brazil

November 30, 2020

L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Reduction in neutralization by some, but not all EUA monoclonal antibody treatments                                Reduced neutralization by convalescent and post-vaccination sera

P.2

Brazil

April 15, 2020

 E484K, (F565L*), D614G, V1176F

Potential reduction in neutralization by monoclonal antibody treatments

Reduced neutralization by post-vaccination sera

B.1.525

United Kingdom, Nigeria

December 11, 2020

A67V, Δ69/70, Δ144, E484K, D614G, Q677H, F888L

Potential reduction in neutralization by monoclonal antibody treatments

Potential reduction in neutralization by convalescent and post-vaccination sera

B.1.526

United States-(New York)

November 23, 2020

(L5F*), T95I, D253G, (S477N*), (E484K*), D614G, (A701V*)

Reduced neutralization by some, but not all EUA monoclonal antibody treatments

Reduced neutralization by convalescent and post-vaccination sera

B.1.427

United States-(California)

March 15, 2020

L452R, D614G

~20% increased transmissibility

Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments

Moderate reduction in neutralization using convalescent and post-vaccination sera

B.1.429

United States-(California)

April 15, 2020

S13I, W152C,L452R, D614G

~20% increased transmissibility

Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments

Moderate reduction in neutralization using convalescent and post-vaccination sera

B.1.617

India

February 25, 2021

Under research

Under research

References:

https://cov-lineages.org/lineages.html

https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html